International Ophthalmology

, Volume 30, Issue 4, pp 425–428 | Cite as

Successful treatment of choroidal neovascular membrane in retinitis pigmentosa with intravitreal bevacizumab

Case Report


We report a rare association of choroidal neovascularization (CNV) with retinitis pigmentosa and note its resolution by intravitreal injection of the anti-vascular endothelial growth factor (VEGF), bevacizumab. A classic choroidal neovascular membrane was seen in the right eye (RE) of a patient with sector retinitis pigmentosa. Bevacizumab 1.25 mg in 0.05 ml was injected intravitreally. The choroidal neovascular membrane was seen to regress following this single intravitreal bevacizumab injection with formation of a scar. CNV has very rarely been seen in association with retinitis pigmentosa. Anti-VEGF drugs have been shown to have a beneficial role in CNV with other causes; in this case their effectiveness in CNV associated with retinal dystrophies, for example retinitis pigmentosa, has been demonstrated.


Anti-VEGF Bevacizumab Choroidal neovascular membrane Retinitis pigmentosa 


  1. 1.
    Bressler NM, Bressler SB, Fine SL (2005) Neovascular (exudative) age related macular degeneration. In: Ryan SJ (ed) Retina, 4th edn. Elsevier Mosby, St. Louis, pp 1075–1111Google Scholar
  2. 2.
    Marano F, Deutman AF, Leys A, Aandekerk AL (2000) Hereditary retinal dystrophies and choroidal neovascularization. Graefe’s Arch Clin Exp Ophthalmol 238:760–764CrossRefGoogle Scholar
  3. 3.
    Iwakiri R, Okinami S, Hirata A (2007) Two cases of retinitis pigmentosa associated with choroidal neovascularisation. Nippon Ganka Gakkai Zasshi 111:606–611PubMedGoogle Scholar
  4. 4.
    Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Arch Ophthalmol 117:1329–1345Google Scholar
  5. 5.
    Reichel E, Berrocal AM, Ip M, Kroll AJ, Duker JS, Puliafito CA (1999) Transpupillary thermotherapy of occult choroidal neovascularization in patients with age-related macular degeneration. Ophthalmology 106:1908–1914CrossRefPubMedGoogle Scholar
  6. 6.
    Bergink GJ, Deutman AF, Van Daal WAJ (1992) Radiation therapy for subfoveal choroidal neovascular membranes in age-related macular degeneration: a pilot study. Int Ophthalmol 16:16Google Scholar
  7. 7.
    Fung WE (1991) Interferon alpha 2a for treatment of age-related macular degeneration. Am J Ophthalmol 112:349–350PubMedGoogle Scholar
  8. 8.
    Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363–372CrossRefPubMedGoogle Scholar
  9. 9.
    Chan WM, Lai TY, Liu DT, Lam DS (2007) Intravitreal bevacizumab (avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 114:2190–2196CrossRefPubMedGoogle Scholar
  10. 10.
    Chan WM, Lai TY, Liu DT, Lam DS (2007) Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 143:977–983CrossRefPubMedGoogle Scholar
  11. 11.
    Leu J, Schrage NF, Degenring RF (2007) Choroidal neovascularisation secondary to Best’s disease in a 13-year-old boy treated by intravitreal bevacizumab. Graefe’s Arch Clin Exp Ophthalmol 245:1723–1725CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  1. 1.Department of OphthalmologyGovernment Medical College HospitalChandigarhIndia

Personalised recommendations